Physician profile
Patrick John Recio
NPI 1023064318
$1,435.81
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $477 · 2021: $69.05 · 2022: $274 · 2023: $267 · 2024: $33.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $264.97 | 2019-2021 | |
| Smith+Nephew, INC. | $261.52 | 2020-2024 | Stravix Pl, Grafix, Stravix |
| Musculoskeletal Transplant Foundation INC. | $204.85 | 2020 | |
| Integra Lifesciences Corporation | $184.96 | 2020-2022 | |
| Kerecis Limited | $148.50 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Si-Bone, INC. | $115.96 | 2019 | |
| Abbott Laboratories | $103.17 | 2022 | |
| Janssen Pharmaceuticals, INC | $57.24 | 2023 | Xarelto |
| Ethicon US, LLC | $34.93 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.95 | 2023 | Gattex |
| Braintree Laboratories, INC. | $16.34 | 2021 | |
| Boston Scientific Corporation | $15.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Recio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.